Abrogating monoacylglycerol acyltransferase activity in liver improves glucose tolerance and hepatic insulin signaling in obese mice.
about
Does Diacylglycerol Accumulation in Fatty Liver Disease Cause Hepatic Insulin Resistance?Inhibited insulin signaling in mouse hepatocytes is associated with increased phosphatidic acid but not diacylglycerol.Inhibiting monoacylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities but not inflammation and injury in miceHepatic Steatosis as a Marker of Metabolic Dysfunction.Hyperinsulinemia Enhances Hepatic Expression of the Fatty Acid Transporter Cd36 and Provokes Hepatosteatosis and Hepatic Insulin Resistance.Characterization of the Mouse and Human Monoacylglycerol O-Acyltransferase 1 (Mogat1) Promoter in Human Kidney Proximal Tubule and Rat Liver Cells.Disparate metabolic response to fructose feeding between different mouse strainsMogat1 deletion does not ameliorate hepatic steatosis in lipodystrophic (Agpat2-/-) or obese (ob/ob) mice.The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities.Suppression of PPARγ-mediated monoacylglycerol O-acyltransferase 1 expression ameliorates alcoholic hepatic steatosis.Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance.PPARs and nonalcoholic fatty liver disease.Gene expression modulation of lipid and central energetic metabolism related genes by high-fat diet intake in the main homeostatic tissues.Hepatocyte-Specific Deletion of Mouse Lamin A/C Leads to Male-Selective Steatohepatitis.Monoacylglycerol O-acyltransferase 1 (MGAT1) localizes to the ER and lipid droplets promoting triacylglycerol synthesis.MOGAT2: A New Therapeutic Target for Metabolic Syndrome.Hepatocyte-specific, PPARγ-regulated mechanisms to promote steatosis in adult mice.Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases.Targeting Hepatic Glycerolipid Synthesis and Turnover to Treat Fatty Liver Disease
P2860
Q26798161-D1AD5A61-0BA2-4E51-968D-F01140B2935DQ30301111-411FC9B4-DC0D-46D4-9D83-C1687B223B96Q34397051-1844CD16-D51A-4F83-A899-62F1D65AF452Q35809069-88E45B84-A51A-463D-A750-31BB3478BAFAQ35905331-82F41281-2D91-4926-8DD1-7FE70A598DE7Q36128458-B3081D57-816C-490F-A938-8EAB38BBDC44Q36392668-6D3EE8F7-4707-42A1-A811-972A9E0C1B51Q36731759-E11BFC93-FE19-42F4-95D1-97C272DC93F6Q37024780-0F7F14B7-A915-4EF3-BA94-5691795E3D05Q37086815-5C3E75CA-2ED7-4A4D-B60A-1779DCB9CA3AQ38760082-F8668717-A59C-4552-827B-802591A3587DQ39029023-B827AF08-72A9-4FC0-8ECC-B165C73C06BFQ39076546-22DABF95-63E1-48C9-98C2-2A69B55465EAQ41602786-BBD9D60D-A2F7-44E1-BF07-F4E593764314Q41616113-5221FA3B-ED31-42A9-A5C4-8D920879CAA9Q42343443-C7B44199-F2F5-4234-910E-4928ECC2CCC2Q47152443-486F57AE-D22E-4ED8-9C77-22C87EEE8824Q47779219-12507890-4297-4228-94F1-09AF4CA5A961Q59049645-03C4FFC6-A0C5-4CFF-AEC3-90A34E41888E
P2860
Abrogating monoacylglycerol acyltransferase activity in liver improves glucose tolerance and hepatic insulin signaling in obese mice.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Abrogating monoacylglycerol ac ...... sulin signaling in obese mice.
@ast
Abrogating monoacylglycerol ac ...... sulin signaling in obese mice.
@en
type
label
Abrogating monoacylglycerol ac ...... sulin signaling in obese mice.
@ast
Abrogating monoacylglycerol ac ...... sulin signaling in obese mice.
@en
prefLabel
Abrogating monoacylglycerol ac ...... sulin signaling in obese mice.
@ast
Abrogating monoacylglycerol ac ...... sulin signaling in obese mice.
@en
P2093
P2860
P921
P356
P1433
P1476
Abrogating monoacylglycerol ac ...... sulin signaling in obese mice.
@en
P2093
Brian N Finck
Derek M Erion
George G Schweitzer
Kari T Chambers
Kyle S McCommis
Mark J Graham
Nisreen Soufi
Zhouji Chen
P2860
P304
P356
10.2337/DB13-1502
P407
P577
2014-03-04T00:00:00Z